Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALUMIS INC.ALMS · Entity 4816 | Director | June 30, 2026 | July 02, 2026 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 15, 2026 | June 17, 2026 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALUMIS INC.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,553 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 3,553 · Balance 3,553 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2036-06-29 | Direct | 15,528 |
Reported balance
After 2026-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-30 · Grant · Acquired 15,528 · Balance 15,528 F2: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.
F2: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.
NEOGENOMICS INC
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,115 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Sale · Disposed 5,307 · Balance 86,115 |
| Common StockSEC Table I · non-derivative | IndirectLynn Tetrault Rollover IRA | 7,000 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.52 · Expires 2026-06-06 | Direct | 2,136 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,136 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.54 · Expires 2027-05-28 | Direct | 3,448 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 3,448 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.90 · Expires 2028-06-02 | Direct | 3,714 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 3,714 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.76 · Expires 2028-10-11 | Direct | 972 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 972 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2029-06-10 | Direct | 13,882 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 13,882 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2033-08-10 | Direct | 8,353 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8,353 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2034-06-01 | Direct | 8,672 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 8,672 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.28 · Expires 2035-06-01 | Direct | 16,107 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 16,107 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01 | Direct | 11,069 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 11,069 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,970 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 15,970 F1: Once vested, the shares of common stock are not subject to expiration. |
Filing footnotes · ownership attribution and instrument terms
F1: Once vested, the shares of common stock are not subject to expiration.
RHYTHM PHARMACEUTICALS, INC.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,712 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Exercise / conversion · Acquired 4,712 · Balance 11,712 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Exercise / conversion · Disposed 4,712 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units are fully vested. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,324 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Grant · Acquired 2,324 · Balance 2,324 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.55 · Expires 2036-06-23 | Direct | 3,691 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Grant · Acquired 3,691 · Balance 3,691 F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.
F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.
F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 43,680 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.29 · Expires 2033-12-17 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 89,955 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4: 1/36 of the shares subject to the option vested on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2024 Filed Jun 11, 2024 23:04 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantDirector Stock Option (right to buy) · Derivative | 43,680 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001962918-24-000085 · wk-form4_1718147088.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,680 Underlying: Common Stock · 43,680 shares Expires 2034-06-06 F1 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000096 · wk-form4_1717531825.xml · derivative · entry 10 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,254 Underlying: Common Stock · 12,254 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,672 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001077183-24-000096 · wk-form4_1717531825.xml · derivative · entry 9 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,672 Underlying: Common Stock · 8,672 shares Expires 2034-06-01 Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:26 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 6,112 | $15.97 | $97,578.69 |
DisclosureSEC source: 0001077183-24-000034 · wk-form4_1709760358.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,062 Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:53 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantDirector Stock Option (right to buy) · Derivative | 89,955 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-23-059383 · doc4.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,955 Underlying: Common Stock · 89,955 shares Expires 2033-12-17 F1 · derivative.exercise_date: 1/36 of the shares subject to the option vest on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying_shares: 1/36 of the shares subject to the option vest on January 18, 2024, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000116 · wk-form4_1692049037.xml · derivative · entry 8 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000116 · wk-form4_1692049037.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-074299 · tm2319485-5_4seq1.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001104659-23-074299 · tm2319485-5_4seq1.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2033-06-20 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001077183-23-000064 · wf-form4_168496374962456.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,507 shares Expires 2023-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 1,507 | $11.60 | $17,481.20 |
DisclosureSEC source: 0001077183-23-000064 · wf-form4_168496374962456.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 13,882 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001077183-22-000107 · wf-form4_165525365169698.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,882 Underlying: Common Stock · 13,882 shares Expires 2029-06-10 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000107 · wf-form4_165525365169698.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,667 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001104659-22-070114 · tm2218129-4_4seq1.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 8, 2023 or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| May 18, 2022 Filed May 20, 2022 21:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,334 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001077183-22-000087 · wf-form4_165308090690889.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2022-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 25, 2017, Lynn Tetrault was granted 10,000 stock options. The options vest ratably on the next three anniversary dates of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 21:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 3,334 | $7.27 | $24,238.18 |
DisclosureSEC source: 0001077183-22-000087 · wf-form4_165308090690889.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 21:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 972 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001077183-21-000227 · wf-form4_163415907002611.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972 Underlying: Common Stock · 972 shares Expires 2028-10-11 Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 21:04 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 838 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000227 · wf-form4_163415907002611.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,777 Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,389 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001077183-21-000168 · wf-form4_162370485942931.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,389 shares Expires 2021-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On July 28, 2016, Lynn Tetrault was granted 8,333 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 1,389 | $9.11 | $12,653.79 |
DisclosureSEC source: 0001077183-21-000168 · wf-form4_162370485942931.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:06 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.99 | $0.00 |
DisclosureSEC source: 0001104659-21-080109 · tm2119501-6_4seq1.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The options fully vest upon the earlier of (i) June 9, 2022 or (ii) the date of the Issuer's next annual meeting of the stockholders. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 3,714 | $0.00 Strike: $40.90 | $0.00 |
DisclosureSEC source: 0001077183-21-000158 · wf-form4_162285104607570.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,714 Underlying: Common Stock · 3,714 shares Expires 2028-06-02 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000158 · wf-form4_162285104607570.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,550 F1 · balance_after: Since the date of the reporting person's last report, Ms. Tetrault transferred 13,882 shares of NEO common stock to a former indirect beneficial owner pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by the former indirect beneficial owner. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $28.27 | $0.00 |
DisclosureSEC source: 0001104659-20-134779 · tm2038260-4_4seq1.xml · derivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: One-third of the options will vest on each one-year anniversary of the grant date, with the first one-third vesting on December 9, 2021. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 3,448 | $0.00 Strike: $28.54 | $0.00 |
DisclosureSEC source: 0001077183-20-000133 · wf-form4_159105224012827.xml · derivative · entry 6 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 Underlying: Common Stock · 3,448 shares Expires 2027-05-28 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 22:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 2,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000133 · wf-form4_159105224012827.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,351 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Options (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000112 · wf-form4_156021597883749.xml · derivative · entry 5 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,269 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Read SEC document |
| June 06, 2019 Filed Jun 11, 2019 01:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000112 · wf-form4_156021597883749.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,653 Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 18:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 2,000 | $15.97 | $31,940.00 |
DisclosureSEC source: 0001077183-18-000121 · wf-form4_154282516716166.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,234 Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 18:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 11,000 | $16.00 | $176,000.00 |
DisclosureSEC source: 0001077183-18-000121 · wf-form4_154282516716166.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,234 Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 3,333 shares Expires 2022-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 25, 2017, Lynn Tetrault was granted 10,000 stock options. The options vest ratably on the next three anniversary dates of the grant date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,555 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · derivative · entry 6 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,778 Underlying: Common Stock · 5,555 shares Expires 2021-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On July 28, 2016, Lynn Tetrault was granted 8,333 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · derivative · entry 5 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On July 15, 2015, Lynn Tetrault was granted 10,000 stock options. The options vest ratably on the next three anniversary dates of the grant date. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 3,333 | $7.27 | $24,230.91 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · nonDerivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 5,555 | $9.11 | $50,606.05 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 10,000 | $6.66 | $66,600.00 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 5,000 | $16.16 | $80,800.00 |
DisclosureSEC source: 0001077183-18-000119 · wf-form4_154240667556312.xml · nonDerivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,234 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 3,017 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001077183-18-000047 · wf-form4_152823543078587.xml · derivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,017 Underlying: Common Stock · 3,017 shares Expires 2023-06-01 Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-18-000047 · wf-form4_152823543078587.xml · nonDerivative · entry 1 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,346 Read SEC document |
| May 30, 2017 Filed May 31, 2017 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | ConversionRestricted Stock · Derivative | 5,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036319 · doc4.xml · derivative · entry 4 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,072 shares Expires 2017-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · kind: Restricted stock has vested and restricted stock certificate issued for shares of the company's common stock. F4 · derivative.exercise_date: 1,690.6 shares will vest on September 30, 2016 and thereafter, 1,690.7 shares will vest on the last day of each calendar quarter for the next two fiscal quarters up to March 31, 2017. Read SEC document |
| May 30, 2017 Filed May 31, 2017 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | ConversionRestricted Stock · Derivative | 2,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036319 · doc4.xml · derivative · entry 3 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,150 shares Expires 2017-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · kind: Restricted stock has vested and restricted stock certificate issued for shares of the company's common stock. F3 · derivative.exercise_date: 537.5 shares will vest on June 30, 2016 and thereafter, 537.5 shares will vest on the last day of each calendar quarter for the next three fiscal quarters up to March 31, 2017. Read SEC document |
| May 30, 2017 Filed May 31, 2017 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 7,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036319 · doc4.xml · nonDerivative · entry 2 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 31, 2017 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock · Derivative | 8,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036319 · doc4.xml · derivative · entry 8 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock · 8,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F8 · derivative.exercise_date: The restricted stock will vest as follows; 2,166 units at June 30, 2017 and thereafter, 2,167 shares will vest on the last day of each calendar quarter for the next three fiscal quarters up to March 31, 2018. F9 · derivative.expiration_date: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| May 25, 2017 Filed May 31, 2017 01:30 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $7.27 Strike: $7.27 | $72,700.00 |
DisclosureSEC source: 0001209191-17-036319 · doc4.xml · derivative · entry 7 TETRAULT LYNN A. · CIK 0001645512 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2022-05-25 F7 · derivative.exercise_date: On May 25, 2017, Lynn Tetrault was granted 10,000 stock options. The options vest ratably on the next three anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.